SRR27320694
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 50.83333333
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INFLAMMATORY_RESPONSE+0.340
- PANCREAS_BETA_CELLS+0.340
- IL6_JAK_STAT3_SIGNALING+0.310
- KRAS_SIGNALING_DN+0.300
- ALLOGRAFT_REJECTION+0.280
- MYOGENESIS+0.260
- INTERFERON_GAMMA_RESPONSE+0.250
- UV_RESPONSE_DN+0.250
- APICAL_SURFACE+0.240
- HEDGEHOG_SIGNALING+0.230
Top 10 suppressed
- MYC_TARGETS_V1-0.670
- OXIDATIVE_PHOSPHORYLATION-0.640
- MYC_TARGETS_V2-0.630
- DNA_REPAIR-0.490
- E2F_TARGETS-0.470
- MTORC1_SIGNALING-0.440
- UNFOLDED_PROTEIN_RESPONSE-0.370
- G2M_CHECKPOINT-0.350
- PROTEIN_SECRETION-0.350
- PI3K_AKT_MTOR_SIGNALING-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 640b257c-bbc3-4483-a7b5-191bb7ef5421 | — | — | 0.926 |
| 2 | TCGA-98-A53C-01A-11R-A262-07 | — | cohortMD2 | 0.917 |
| 3 | SRR1362464 | GTEX | — | 0.915 |
| 4 | TCGA-DK-AA6S-01A-21R-A39I-07 | — | — | 0.906 |
| 5 | BS_VTJ9ESSV | DNET | — | 0.905 |
| 6 | SRR6013548 | — | cohortA1 | 0.904 |
| 7 | SRR817758 | GTEX | — | 0.903 |
| 8 | TCGA-98-A53H-01A-12R-A262-07 | — | cohortA1 | 0.900 |
| 9 | MNG809 | — | — | 0.897 |
| 10 | DRR168582 | — | — | 0.897 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INFLAMMATORY_RESPONSE | 0.340 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.340 | Cobimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.310 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.280 | Idelalisib | — uncovered |
| MYOGENESIS | 0.260 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.250 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.250 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.240 | Temsirolimus | — uncovered |
| HEDGEHOG_SIGNALING | 0.230 | Inavolisib | — uncovered |
| COMPLEMENT | 0.220 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.200 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.200 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.190 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.170 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.120 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| SPERMATOGENESIS | 0.090 | Inavolisib | — uncovered |
| COAGULATION | 0.080 | Binimetinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.080 | Inavolisib | — uncovered |